Supplementary Figures 1 - 5 from High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma

PDF file - 62K, Treatment of two Ewing sarcoma cell lines with A, dasatinib (SRC inhibitor) for 8 hours or B, PD0325901 (MEK inhibitor) for 72 hours eliminates phosphorylation of SRC and ERK, respectively (S1); Transduction with five FAK-directed shRNAs downregulate FAK expression compared to a control shRNA in the A673 Ewing sarcoma cell line (S2); Treatment of A673 and TC32 Ewing sarcoma cell lines with PF-562271 reduced cell growth (S3); Treatment of Ewing sarcoma cell lines with PF- 562271 impairs cell growth (S4); PYK2 is variably expressed in Ewing sarcoma cell lines (S5).